Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study

Background: Recently, calreticulin (CALR) gene mutations have been identified in patients with essential thrombocythemia (ET). A high-frequency of ET cases without Janus kinase 2 (JAK2) mutations contain CALR mutations and exhibit clinical characteristics different from those with mutant JAK2. Thus,...

Full description

Bibliographic Details
Main Authors: Chao Sun, Xin Zhou, Zhi-Jian Zou, Hong-Feng Guo, Jian-Yong Li, Chun Qiao
Format: Article
Language:English
Published: Wolters Kluwer 2016-01-01
Series:Chinese Medical Journal
Subjects:
Online Access:http://www.cmj.org/article.asp?issn=0366-6999;year=2016;volume=129;issue=15;spage=1778;epage=1783;aulast=Sun
_version_ 1818843191894343680
author Chao Sun
Xin Zhou
Zhi-Jian Zou
Hong-Feng Guo
Jian-Yong Li
Chun Qiao
author_facet Chao Sun
Xin Zhou
Zhi-Jian Zou
Hong-Feng Guo
Jian-Yong Li
Chun Qiao
author_sort Chao Sun
collection DOAJ
description Background: Recently, calreticulin (CALR) gene mutations have been identified in patients with essential thrombocythemia (ET). A high-frequency of ET cases without Janus kinase 2 (JAK2) mutations contain CALR mutations and exhibit clinical characteristics different from those with mutant JAK2. Thus, we investigated the frequency and clinical features of Chinese patients of Han ethnicity with CALR mutations in ET. Methods: We recruited 310 Chinese patients of Han ethnicity with ET to analyze states of CALR, JAK2V617F, and MPLW515 mutations by polymerase chain reaction and direct sequencing. We analyzed the relationship between the mutations and clinical features. Results: CALR, JAK2V617F, and MPLW515 mutations were detected in 30% (n = 92), 48% (n = 149), and 1% (n = 4) of patients with ET, respectively. The mutation types of CALR involved deletion and insertion of base pairs. Most of them were Type 1 (52-bp deletion) and Type 2 (5-bp insertion, TTGTC) mutations, leading to del367fs46 and ins385fs47, respectively. The three mutations were exclusive. Clinically, patients with mutated CALR had a lower hemoglobin level, lower white blood cell (WBC) count, and higher platelet count compared to those with mutated JAK2 (P < 0.05). Furthermore, a significant difference was found in WBCs between wild-type patients (triple negative for JAK2, MPL, and CALR mutations) and patients with JAK2 mutations. Patients with CALR mutations predominantly clustered into low or intermediate groups according to the International Prognostic Score of thrombosis for ET (P < 0.05). Conclusions: CALR mutations were frequent in Chinese patients with ET, especially in those without JAK2 or MPL mutations. Compared with JAK2 mutant ET, CALR mutant ET showed a different clinical manifestation and an unfavorable prognosis. Thus, CALR is a potentially valuable diagnostic marker and therapeutic target in ET.
first_indexed 2024-12-19T04:53:57Z
format Article
id doaj.art-8422c2092ed74f7b9e62a10564167fac
institution Directory Open Access Journal
issn 0366-6999
language English
last_indexed 2024-12-19T04:53:57Z
publishDate 2016-01-01
publisher Wolters Kluwer
record_format Article
series Chinese Medical Journal
spelling doaj.art-8422c2092ed74f7b9e62a10564167fac2022-12-21T20:35:16ZengWolters KluwerChinese Medical Journal0366-69992016-01-01129151778178310.4103/0366-6999.186641Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical StudyChao SunXin ZhouZhi-Jian ZouHong-Feng GuoJian-Yong LiChun QiaoBackground: Recently, calreticulin (CALR) gene mutations have been identified in patients with essential thrombocythemia (ET). A high-frequency of ET cases without Janus kinase 2 (JAK2) mutations contain CALR mutations and exhibit clinical characteristics different from those with mutant JAK2. Thus, we investigated the frequency and clinical features of Chinese patients of Han ethnicity with CALR mutations in ET. Methods: We recruited 310 Chinese patients of Han ethnicity with ET to analyze states of CALR, JAK2V617F, and MPLW515 mutations by polymerase chain reaction and direct sequencing. We analyzed the relationship between the mutations and clinical features. Results: CALR, JAK2V617F, and MPLW515 mutations were detected in 30% (n = 92), 48% (n = 149), and 1% (n = 4) of patients with ET, respectively. The mutation types of CALR involved deletion and insertion of base pairs. Most of them were Type 1 (52-bp deletion) and Type 2 (5-bp insertion, TTGTC) mutations, leading to del367fs46 and ins385fs47, respectively. The three mutations were exclusive. Clinically, patients with mutated CALR had a lower hemoglobin level, lower white blood cell (WBC) count, and higher platelet count compared to those with mutated JAK2 (P < 0.05). Furthermore, a significant difference was found in WBCs between wild-type patients (triple negative for JAK2, MPL, and CALR mutations) and patients with JAK2 mutations. Patients with CALR mutations predominantly clustered into low or intermediate groups according to the International Prognostic Score of thrombosis for ET (P < 0.05). Conclusions: CALR mutations were frequent in Chinese patients with ET, especially in those without JAK2 or MPL mutations. Compared with JAK2 mutant ET, CALR mutant ET showed a different clinical manifestation and an unfavorable prognosis. Thus, CALR is a potentially valuable diagnostic marker and therapeutic target in ET.http://www.cmj.org/article.asp?issn=0366-6999;year=2016;volume=129;issue=15;spage=1778;epage=1783;aulast=SunCalreticulin; Essential Thrombocythemia; Gene Mutation; Janus Kinase 2
spellingShingle Chao Sun
Xin Zhou
Zhi-Jian Zou
Hong-Feng Guo
Jian-Yong Li
Chun Qiao
Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study
Chinese Medical Journal
Calreticulin; Essential Thrombocythemia; Gene Mutation; Janus Kinase 2
title Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study
title_full Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study
title_fullStr Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study
title_full_unstemmed Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study
title_short Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study
title_sort clinical manifestation of calreticulin gene mutations in essential thrombocythemia without janus kinase 2 and mpl mutations a chinese cohort clinical study
topic Calreticulin; Essential Thrombocythemia; Gene Mutation; Janus Kinase 2
url http://www.cmj.org/article.asp?issn=0366-6999;year=2016;volume=129;issue=15;spage=1778;epage=1783;aulast=Sun
work_keys_str_mv AT chaosun clinicalmanifestationofcalreticulingenemutationsinessentialthrombocythemiawithoutjanuskinase2andmplmutationsachinesecohortclinicalstudy
AT xinzhou clinicalmanifestationofcalreticulingenemutationsinessentialthrombocythemiawithoutjanuskinase2andmplmutationsachinesecohortclinicalstudy
AT zhijianzou clinicalmanifestationofcalreticulingenemutationsinessentialthrombocythemiawithoutjanuskinase2andmplmutationsachinesecohortclinicalstudy
AT hongfengguo clinicalmanifestationofcalreticulingenemutationsinessentialthrombocythemiawithoutjanuskinase2andmplmutationsachinesecohortclinicalstudy
AT jianyongli clinicalmanifestationofcalreticulingenemutationsinessentialthrombocythemiawithoutjanuskinase2andmplmutationsachinesecohortclinicalstudy
AT chunqiao clinicalmanifestationofcalreticulingenemutationsinessentialthrombocythemiawithoutjanuskinase2andmplmutationsachinesecohortclinicalstudy